California Institute of Technology

Forge Therapeutics, Inc.

Konstantin Taganov

David Baltimore

Mark Boldin

Min Teng

David Thomas Puerta

Baskar Nammalwar

Ryan Michael O'Connell

Xiaoming Li

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. Furthermore, the subject compounds and compositions are useful for the treatment of bacterial infection, such as urinary tract infection and the like.

Antibacterial compounds

The present teachings relate to hydroxypyrimidinone derivatives of Formula II, pharmaceutical compositions thereof, and methods of using such compounds to treat bacterial infections. 

Substituted pyrimidines for treating bacterial infections

The present teachings relate to pyrone derivatives, pharmaceutical compositions thereof, and methods of using such compounds to treat bacterial infections.

Pyrone based compounds for treating bacterial infections

The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arntl, Picalm, Jarid2, PU.1, Csf1r, HIF1&#x3b1;, Sla, Cepb&#x3b2;, and Bach1, and the like.

MicroRNA inhibition for the treatment of inflammation and myeloproliferative disorders

The present teachings relate to hydroxypyrimidinone derivatives of Formula IV, pharmaceutical compositions thereof, and methods of using such compounds to treat bacterial infections. 

Substituted hydroxypyrimidinones for treating bacterial infections

The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arnt1, Picalm, Jarid2, PU.1, Csf1r, HIF1&#x3b1;, Sla, Cebp&#x3b2;, and Bach1, and the like.

Microrna inhibition for the treatment of inflammation and myeloproliferative disorders

The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing an treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arntl, Picalm, Jarid2, PU.1, Csflr, HIF1&#x3b1;, Sla, Cepb&#x3b2;, and Bach1, and the like.

The present disclosure relates to the finding that microRNA-146 plays a role in modulating the development and function of the immune system. Immune cell development and function can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells or precursor cells. For example, in some embodiments, activity and/or proliferation of certain immune cells is regulated by administering miR-146 oligonucleotides or anti-miR-146 oligonucleotides. In other embodiments, pro-inflammatory cytokine expression in immune cells is regulated by administering a miR-146 oligonucleotide or anti-miR-146. In further embodiments, methods of regulating macrophage activity using antisense miR-146 are provided. Additional methods and compositions for regulating immune system function and development using miR-146 are disclosed.

Modulating immune system development and function through microRNA MIR-146

The present disclosure relates to the finding that microRNA-155 plays a role in inflammation, hematopoiesis and myeloproliferation, and that dysregulation of microRNA-155 expression is associated with particular myeloproliferative disorders. Disclosed herein are methods and compositions for diagnosing and treating disorders, including inflammation and myeloproliferation, modulating the levels of expression of one or more genes selected from the group consisting of Cutl1, Arnt1, Picalm, Jarid2, PU.1, Csf1r, HIF1&#x3b1;, Sla, Cepb&#x3b2;, and Bach1, and the like.

The present disclosure relates to the finding that microRNA-146 plays a role modulating the innate immune response. Innate immunity receptor signaling can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells. In some embodiments, IL-1 receptor associated kinase 1 (IRAK1) and TNF receptor associated factor 6 (TRAF6) expression levels are downregulated in a target cell by administering a miR-146 oligonucleotide. Modulation of the innate immune system through miR-146 can be used to treat a variety of diseases and disorders associated with activation of the innate immune system, such as sepsis and Crohn's disease.

Growing community of inventors

Pasadena, CA, United States of America

Konstantin Taganov